HIV Entry Inhibition

Phase I trial initiated for new anti-HIV drug candidate AMD070

Published in AIDS Weekly, September 29th, 2003

AnorMED, Inc., (AOM) has initiated enrollment into a phase I trial in healthy volunteers to evaluate the safety of AMD070 for the treatment of HIV infection.

AMD070 targets the CXCR4 chemokine receptor and prevents HIV from entering and infecting healthy cells. CXCR4 and CCR5 inhibitors belong to the new investigational class of antiretroviral drugs known as HIV entry inhibitors.

"Recent clinical results indicate that CXCR4 using strains of HIV affect approximately 40% of patients and that these strains are more damaging to the immune system than CCR5 using strains. Given the increasing amount of evidence we believe CXCR4 inhibitors have an important...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-09-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry